Page last updated: 2024-11-06

isaxonine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Isaxonine is a naturally occurring alkaloid isolated from the bark of the African tree *Erythrophleum suaveolens*. It exhibits potent anti-inflammatory and analgesic effects, potentially acting as a selective inhibitor of the enzyme phospholipase A2. Research into isaxonine focuses on its potential therapeutic applications in treating inflammatory diseases like rheumatoid arthritis and osteoarthritis. Its unique structure and biological activity have also made it a subject of investigation for the development of new drug candidates.'

isaxonine: promotes nerve growth [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID71169
CHEMBL ID1740513
CHEBI ID134762
SCHEMBL ID1270289
MeSH IDM0074028

Synonyms (50)

Synonym
isopropyl-pyrimidin-2-yl-amine
isaxonine
CHEBI:134762
2-(isopropylamino)pyrimidine
n-propan-2-ylpyrimidin-2-amine
NCGC00183018-01
HMS3264O13
4214-72-6
2-pyrimidinamine, n-(1-methylethyl)-
pharmakon1600-01504617
nsc760406
isaxonina [inn-spanish]
883g6dmt63 ,
isaxonine [inn]
isaxonina
unii-883g6dmt63
nsc 760406
isaxoninum
isaxoninum [inn-latin]
nsc-760406
CHEMBL1740513
AKOS008922287
AM100809
isaxonine [who-dd]
isaxonine [mi]
FTCYIGBVOHNHCD-UHFFFAOYSA-N
2-isopropylamino pyrimidine
isopropylamino-pyrimidine
2-isopropylamino-pyrimidine
n-isopropylpyrimidin-2-amine
CCG-213955
SCHEMBL1270289
AB01563225_01
F8881-7943
n-(propan-2-yl)pyrimidin-2-amine
2-(n-isopropylamino)pyrimidine
DTXSID20194975
Z31190928
sr-01000872732
SR-01000872732-1
AS-59517
n-isopropylpyrimidin-2-yl-amine
mfcd00867809
BRD-K95957366-001-01-8
C75128
Q27269878
SB57786
A872944
CS-0187589
EN300-227083

Research Excerpts

Overview

summarize : . Then isaxonine acts as a modifier of the surface pH of the bilayer.

ExcerptReferenceRelevance
"Then isaxonine acts as a modifier of the surface pH of the bilayer."( Isaxonine base is a strong perturber of phospholipid bilayer order and fluidity--a differential scanning calorimetry and spin labeling study.
Berleur, F; Braquet, P; Esanu, A; Jaskierowicz, D; Leterrier, F; Madelmont, G; Roman, V; ter-Minassian-Saraga, L, 1984
)
2.17

Effects

Isaxonine has no direct effect on a diseased muscle with an intact nerve supply, nor in the early stages after complete denervation.

ExcerptReferenceRelevance
"Isaxonine has specific affinity for peripheral nerves."( [Pharmacological basis of the action of isaxonine (author's transl)].
Hugelin, A, 1982
)
1.25
"Isaxonine has no direct effect on a diseased muscle with an intact nerve supply, nor in the early stages after complete denervation."( Influence of isaxonine on the target phenomenon, muscle fibre size and neuromuscular junction in the tenotomized and denervated gastrocnemius muscle of the rat.
Blancquaert, JP; De Bleecker, J; De Coster, W; De Reuck, J, 1986
)
1.36

Dosage Studied

ExcerptRelevanceReference
" The dosage of 1175 to 1500 mg/day for adults seemed adequate."( [Clinical trial of isaxonine in alcoholic polyneuritis (author's transl)].
Cadilhac, J; Passouant, P, 1982
)
0.59
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aminopyrimidineA member of the class of pyrimidines that is pyrimidine substituted by at least one amino group and its derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (23)

Assay IDTitleYearJournalArticle
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID625276FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of most concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID625293Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in LTKB-BD2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (52)

TimeframeStudies, This Drug (%)All Drugs %
pre-199043 (82.69)18.7374
1990's6 (11.54)18.2507
2000's0 (0.00)29.6817
2010's3 (5.77)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials12 (21.43%)5.53%
Reviews3 (5.36%)6.00%
Case Studies8 (14.29%)4.05%
Observational0 (0.00%)0.25%
Other33 (58.93%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]